T cells redirected by a CD3ζ chimeric antigen receptor can establish self-antigen-specific tumour protection in the long term

TCR Gene Therapy of Spontaneous Prostate Carcinoma Requires In Vivo T Cell Activation

(2014) M. A. de Witte et al.   JOURNAL OF IMMUNOLOGY

IL-12 Release by Engineered T Cells Expressing Chimeric Antigen Receptors Can Effectively Muster an Antigen-Independent Macrophage Response on Tumor Cells That Have Shut Down Tumor Antigen Expression

(2011) M. Chmielewski et al.   CANCER RESEARCH

CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients

(2011) Barbara Savoldo et al.   JOURNAL OF CLINICAL INVESTIGATION

CARs on Track in the Clinic

(2011) Donald B Kohn et al.   MOLECULAR THERAPY

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

(2011) M. Kalos et al.   Science Translational Medicine

Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor

(2010) B. Jena et al.   BLOOD

Tumor Ablation by Gene-Modified T Cells in the Absence of Autoimmunity

(2010) L. X. J. Wang et al.   CANCER RESEARCH

Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo

(2009) Michael C. Milone et al.   MOLECULAR THERAPY